Sorafenib suppresses TGF-β responses by inducing caveolae/lipid raft-mediated internalization/degradation of cell-surface type II TGF-β receptors: Implications in development of effective adjunctive therapy for hepatocellular carcinoma

• Main Authors: Chih Ling Chung, Shih Wei Wang, Wei Chih Sun, Chih Wen Shu, Yu Chen Kao, Meng Shin Shiao, Chun Lin Chen
• Other Authors: Veterans General Hospital-Kaohsiung Taiwan
• Format: Article
• Published: 2019
• Subjects: Biochemistry, Genetics and Molecular Biology; Pharmacology, Toxicology and Pharmaceutics
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/45100
• Institution: Mahidol University

© 2018 Elsevier Inc. Sorafenib is the only FDA approved drug for the treatment of advanced hepatocellular carcinoma (HCC) and other malignancies. Studies indicate that TGF-β signalling is associated with tumour progression in HCC. Autocrine and paracrine TGF-β promotes tumour growth and malignancy b...